Tiziana Life Sciences (NASDAQ: TLSA) is one of 538 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Tiziana Life Sciences to similar companies based on the strength of its analyst recommendations, profitability, earnings, dividends, institutional ownership, valuation and risk.
This table compares Tiziana Life Sciences and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Tiziana Life Sciences||N/A||N/A||N/A|
|Tiziana Life Sciences Competitors||-1,966.44%||-103.95%||-25.56%|
This is a summary of current ratings and price targets for Tiziana Life Sciences and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Tiziana Life Sciences||0||0||2||0||3.00|
|Tiziana Life Sciences Competitors||4252||12260||26562||913||2.55|
As a group, “Pharmaceutical preparations” companies have a potential upside of 59.97%. Given Tiziana Life Sciences’ rivals higher probable upside, analysts clearly believe Tiziana Life Sciences has less favorable growth aspects than its rivals.
Valuation and Earnings
This table compares Tiziana Life Sciences and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Tiziana Life Sciences||N/A||-$8.71 million||-71.25|
|Tiziana Life Sciences Competitors||$2.29 billion||$254.29 million||-2.09|
Tiziana Life Sciences’ rivals have higher revenue and earnings than Tiziana Life Sciences. Tiziana Life Sciences is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
46.7% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 15.0% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Tiziana Life Sciences rivals beat Tiziana Life Sciences on 7 of the 12 factors compared.
Tiziana Life Sciences Company Profile
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of therapeutics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Milciclib (TZLS-201) that is in phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy; and Foralumab (TZLS-401), a human anti-CD3 antibody, which completed phase IIa clinical trials for autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, primary biliary cholangitis, ulcerative colitis, multiple sclerosis, autoimmune type-1 diabetes, inflammatory bowel diseases, and lupus. It also develops TZLS-501, a human anti IL-6R monoclonal antibody that is in pre-clinical development. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.